Advertisement

© 2006

Cell Culture Engineering

  • Editors
  • Wei-Shou Hu

Benefits

  • Covers trends in modern biotechnology

  • All aspects of this interdisciplinary technology, where knowledge, methods and expertise are required from chemistry, biochemistry, microbiology, genetics, chemical engineering and computer science, are treated

  • More information as well as the electronic version available at springer.com

Book

Part of the Advances in Biochemical Engineering/Biotechnology book series (ABE, volume 101)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Katie F. Wlaschin, Wei-Shou Hu
    Pages 43-74
  3. Konstantin Konstantinov, Chetan Goudar, Maria Ng, Renato Meneses, John Thrift, Sandy Chuppa et al.
    Pages 75-98
  4. Chetan Goudar, Richard Biener, Chun Zhang, James Michaels, James Piret, Konstantin Konstantinov
    Pages 99-118
  5. Gargi Seth, Patrick Hossler, Joon Chong Yee, Wei-Shou Hu
    Pages 119-164
  6. Back Matter
    Pages 165-168

About this book

Introduction

Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade.

Keywords

Biotechnology Cell Culture Escherichia coli biochemical engineering cell biology post-translational modification protein proteins translation

Bibliographic information

  • Book Title Cell Culture Engineering
  • Editors Wei-Shu Hu
  • Series Title Advances in Biochemical Engineering/Biotechnology
  • DOI https://doi.org/10.1007/11751571
  • Copyright Information Springer-Verlag Berlin Heidelberg 2006
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Chemistry and Materials Science Chemistry and Material Science (R0)
  • Hardcover ISBN 978-3-540-34006-5
  • Softcover ISBN 978-3-642-07051-8
  • eBook ISBN 978-3-540-34007-2
  • Series ISSN 0724-6145
  • Series E-ISSN 1616-8542
  • Edition Number 1
  • Number of Pages XI, 168
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Additional Information With contributions by numerous experts
  • Topics Biotechnology
    Cell Biology
    Biochemistry, general
  • Buy this book on publisher's site
Industry Sectors
Biotechnology
Chemical Manufacturing
Consumer Packaged Goods
Pharma